| Development of drugs for the treatment of HIV infection |
Shionogi and ViiV Healthcare have jointly conducted research and development of dolutegravir, a novel HIV integrase inhibitor. Developing countries account for more than 40% of the global supply volume share of the anti-HIV drug Tebikei (generic name: dolutegravir) and its combination products Trimek and Jaluka, which were licensed out to Vive Healthcare. Dolutegravir is registered in the Medicines Patent Pool, which releases patents free of charge, allowing generic drug manufacturers to manufacture dolutegravir as a single agent or in combination with other anti-HIV drugs and supply them to more than 130 low- and middle-income countries. The patent is free and open. |
